Randomized phase II trial of Herceptin (NSC 688097) [trastuzumab] and weekly docetaxel (NSC 628503) in androgen-independent (hormone refractory) adenocarcinoma of the prostate (CaP).
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2010
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 22 Aug 2006 Status change